These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25011029)

  • 21. Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis.
    Kapoor KG; Wagner AL
    Ophthalmic Res; 2016; 56(1):17-22. PubMed ID: 26982318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy.
    Sadda SR
    Eye (Lond); 2020 Sep; 34(9):1489-1490. PubMed ID: 32042181
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment of central serous chorioretinopathy with mineralocorticoid receptor antagonists].
    Cakir B; Agostini H; Lange C
    Ophthalmologe; 2019 Feb; 116(2):189-200. PubMed ID: 30255262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eplerenone for chronic central serous chorioretinopathy - Authors' reply.
    Lotery A; O'Connell A; Harris RA; Sivaprasad S; Reeves BC
    Lancet; 2020 Nov; 396(10262):1557-1558. PubMed ID: 33189170
    [No Abstract]   [Full Text] [Related]  

  • 25. Reply to: 'Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy'.
    Lotery A; Sivaprasad S; O'Connell A; Reeves B
    Eye (Lond); 2021 Dec; 35(12):3448. PubMed ID: 34089001
    [No Abstract]   [Full Text] [Related]  

  • 26. [Eplerenone treatment in chronic central serous chorioretinopathy].
    Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F
    J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapy Rationale for Mineralocorticoid-Receptor Antagonists, Acetazolamide and a Switch of Therapy in Nonresponders in Central Serous Chorioretinopathy.
    Rübsam A; Thieme CE; Schlomberg J; Winterhalter S; Müller B; Joussen AM; Stübiger N
    J Ocul Pharmacol Ther; 2017 Apr; 33(3):141-148. PubMed ID: 28277988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series.
    Salz DA; Pitcher JD; Hsu J; Regillo CD; Fineman MS; Elliott KS; Vander JF; Fischer DH; Spirn MJ
    Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):439-44. PubMed ID: 25970864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES.
    Gergely R; Kovács I; Schneider M; Resch M; Papp A; Récsán Z; Nagy ZZ; Ecsedy M
    Retina; 2017 Jun; 37(6):1084-1091. PubMed ID: 27627749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
    Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
    Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
    Schwartz R; Habot-Wilner Z; Martinez MR; Nutman A; Goldenberg D; Cohen S; Shulman S; Guzner-Gur H; Loewenstein A; Goldstein M
    Acta Ophthalmol; 2017 Nov; 95(7):e610-e618. PubMed ID: 28653813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.
    Awasthi U; Grover R; Varshney A; Videkar C
    Am J Ophthalmol; 2019 Jul; 203():121. PubMed ID: 31126617
    [No Abstract]   [Full Text] [Related]  

  • 33. Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy.
    Xia Y; Hua R
    Eye (Lond); 2021 Dec; 35(12):3445-3447. PubMed ID: 33257799
    [No Abstract]   [Full Text] [Related]  

  • 34. [Paracentral retinal changes].
    Nentwich MM; Ulbig M
    Klin Monbl Augenheilkd; 2013 Oct; 230(10):1034-5. PubMed ID: 23846325
    [No Abstract]   [Full Text] [Related]  

  • 35. Eplerenone is not superior to placebo for chronic central serous chorioretinopathy.
    Rabiolo A; Bandello F
    Lancet; 2020 Jan; 395(10220):252-253. PubMed ID: 31982052
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR).
    Herold TR; Rist K; Priglinger SG; Ulbig MW; Wolf A
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):221-229. PubMed ID: 27475933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis.
    Daruich A; Matet A; Dirani A; Bousquet E; Zhao M; Farman N; Jaisser F; Behar-Cohen F
    Prog Retin Eye Res; 2015 Sep; 48():82-118. PubMed ID: 26026923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mineralocorticoid receptor antagonists for heart failure.
    Funder J
    Expert Opin Pharmacother; 2011 Dec; 12(18):2767-9. PubMed ID: 22098225
    [No Abstract]   [Full Text] [Related]  

  • 39. Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report.
    Gruszka A
    Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1369-73. PubMed ID: 23740451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mineralocorticoid receptor antagonists: part of an emerging treatment paradigm for chronic kidney disease.
    Epstein M
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):925-7. PubMed ID: 25466241
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.